Management of cutaneous tuberculosis.
Cutaneous tuberculosis (TB) is an extrapulmonary form of tuberculosis, which may be classified based on the immunologic state of the host. Chemotherapy still remains the treatment of choice. The management of cutaneous TB follows the same guidelines as that of TB of other organs, which can be treated with a short course four-agent chemotherapeutic regimen given for 2 months followed by a two-drug regimen for the next 4 months. This chapter highlights current treatment recommendations for cutaneous TB. The important factors to consider in the choice of optimal treatment includes the type of cutaneous involvement, stage of the disease, level of immunity, and general condition of the patient. The highest priority in any cutaneous TB control program is the proper, accurate, and rapid detection of cases and the availability of chemotherapy to all tuberculosis patients until cure. Contact tracing is also an important component of efficient tuberculosis control.
Handog
Evangeline B
EB
Department of Dermatology, Asian Hospital Medical Center, Philippines, and Research Institute for Tropical Medicine, Department of Health, Philippines. handogmd@pacific.net.ph.
Gabriel
Teresita G
TG
Pineda
Rosario Trinidad V
RT
D000328:Adult; D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D004334:Drug Administration Schedule; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D012307:Risk Factors; D012867:Skin / Q000473:pathology; D014382:Tuberculosis, Cutaneous / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology
D000995:Antitubercular Agents